Nd:YAG LaserNCT07678697
Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
A study testing Nd:YAG laser and Diode laser in people with Nd:YAG Laser and Sclerotherapy, run by Ain Shams University at 1 site in Egypt.
Trial summary
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Nd:YAG Laser, Sclerotherapy, Diode Laser
- What is being tested?
- Nd:YAG laser and Diode laser
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2026to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients aged 18-60 years.
- Both sexes.
- Presence of reticular veins and/or telangiectasias (CEAP classification C1).
- Fitzpatrick skin types II-V.
- Patients seeking cosmetic treatment.
Who cannot join
- Pregnancy or lactation.
- History of deep vein thrombosis.
- Coagulation disorders.
- Allergy to sclerosant agents.
- Active skin infection at treatment site.
- Previous treatment of target veins within 6 months.
Show all 9Show fewer
- Great saphenous vein or short saphenous vein incompetence.
- Deep venous insufficiency or thrombosis.
- Abnormal venous duplex findings.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Ain Shams University
Cairo, 11591
Mohamed A Hagag, MD, 00201126560324, hagagmohamed@med.asu.edu.eg
Ahmed G Abdellattif, MD
About this study
Official title: Comparative Study Between Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.
Read the detailed description
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
- Conditions
- Nd:YAG Laser, Sclerotherapy, Diode Laser, Reticular Veins, Telangiectasias, CLaCS Technique
- Being tested
- Nd:YAG laser, Diode laser
- Medical subject headings
- Telangiectasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nd:YAG laserDevice
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).
Diode laserDrug
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
| Study group | Role | What they receive |
|---|---|---|
| Group A (Nd:YAG Group): | Experimental | Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS). Receives: Device: Nd:YAG laser |
| Group B (Diode Group) | Experimental | Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS). Receives: Drug: Diode laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Degree of vein clearance
Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color.
Measured: 6 months postoperatively
Secondary outcomes (5)
Degree of pain
Each patient will be instructed about postoperative pain assessment with VAS. VAS (0 represents "no pain" while 10 represents "the worst pain imaginable").
Measured: 6 months postoperatively
Degree of patient satisfaction
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
Measured: 6 months postoperatively
Incidence of complications
Incidence of complications such as hyperpigmentation, burns, and matting will be recorded.
Measured: 6 months postoperatively
Number of treatment sessions required
Number of treatment sessions required will be recorded.
Measured: 6 months postoperatively
Recurrence rate
Recurrence rate will be recorded.
Measured: 6 months postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study start1 Jun 2026
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nd:YAG LaserStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, MohamedAhmed, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07678697
- Sponsor's protocol ID
- IRB 00006379 (17/05/2026)
- Status last verified
- Jun 2026
- First submitted
- 25 Jun 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study Between Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
- ClinicalTrials.gov ID
- NCT07678697
- Acronym / sponsor ID
- IRB 00006379 (17/05/2026)
- Conditions
- Nd:YAG Laser, Sclerotherapy, Diode Laser, Reticular Veins, Telangiectasias, CLaCS Technique
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 1 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.
Detailed description
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A (Nd:YAG Group): | Experimental | Device: Nd:YAG laserPatients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS). |
| Group B (Diode Group) | Experimental | Drug: Diode laserPatients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS). |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Patients aged 18-60 years.
- Both sexes.
- Presence of reticular veins and/or telangiectasias (CEAP classification C1).
- Fitzpatrick skin types II-V.
- Patients seeking cosmetic treatment.
Key exclusion criteria (9 listed)
- Pregnancy or lactation.
- History of deep vein thrombosis.
- Coagulation disorders.
- Allergy to sclerosant agents.
- Active skin infection at treatment site.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nd:YAG laserPatients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS). | Device | Group A (Nd:YAG Group): |
| Diode laserPatients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS). | Drug | Group B (Diode Group) |
Primary outcome
Degree of vein clearance
Time frame: 6 months postoperatively
Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color.
5 secondary outcomes
Degree of pain
Time frame: 6 months postoperatively
Degree of patient satisfaction
Time frame: 6 months postoperatively
Incidence of complications
Time frame: 6 months postoperatively
Number of treatment sessions required
Time frame: 6 months postoperatively
Recurrence rate
Time frame: 6 months postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Nd:YAG Laser
RecruitingPhase 4
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
Telangiectasias, Reticular Veins
Not yet recruiting
Systemic Antifungal Plus Q-Switched Nd:YAG Laser for Onychomycosis
Onychomycosis
Not yet recruiting
Nd:YAG Laser Photobiomodulation for Neurosensory Recovery Following Bimaxillary Orthognathic Surgery
Infraorbital Nerve Injury, Inferior Alveolar Nerve Injury
Not yet recruitingObservational study
IOL Position and Refractive Change After Nd:YAG Laser Posterior Capsulotomy
Posterior Capsule Opacification, Pseudophakia
Recruiting
Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients
Port Wine Stains
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nd:YAG laser and Diode laser in people with Nd:YAG Laser and Sclerotherapy, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed A Hagag, MD (00201126560324, hagagmohamed@med.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Degree of vein clearance (time frame: 6 months postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.